A5030134444- Multiple Myeloma Research and Treatments
- Hemoglobinopathies and Related Disorders
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Iron Metabolism and Disorders
- Hematopoietic Stem Cell Transplantation
- Chronic Myeloid Leukemia Treatments
- Cytomegalovirus and herpesvirus research
- Lung Cancer Treatments and Mutations
- Radiomics and Machine Learning in Medical Imaging
- CNS Lymphoma Diagnosis and Treatment
- Polyomavirus and related diseases
- Viral-associated cancers and disorders
- Immune Cell Function and Interaction
- Transplantation: Methods and Outcomes
- Eosinophilic Disorders and Syndromes
- Pharmacological Effects and Toxicity Studies
- Folate and B Vitamins Research
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Blood groups and transfusion
- Mesenchymal stem cell research
- Neonatal Respiratory Health Research
- Neonatal Health and Biochemistry
Groupe Hospitalier de l'Institut Catholique de Lille
2015-2025
Hôpital Saint-Vincent-de-Paul
2015-2024
Université Catholique de Lille
2010-2023
Université de Lille
2012-2021
Centre Hospitalier Universitaire de Lille
2015-2021
Lille’s Cardiology Hospital
2011-2016
Unité Mixte de Recherche Epidémiologique et de Surveillance Transport Travail Environnement
2016
Lille Inflammation Research International Center
2015
Université Lille Nord de France
2015
Hôpital Claude Huriez
2009-2011
The prognosis of patients with early-stage unfavorable Hodgkin lymphoma remains unsatisfactory. We assessed the efficacy and safety brentuximab vedotin plus doxorubicin, vinblastine, dacarbazine (BV-AVD) in previously untreated, (ClinicalTrials.gov identifier: NCT02292979). BREACH is a multicenter, randomized, open-label, phase II trial. Eligible were age 18-60 years ≥ 1 EORTC/LYSA criterion. Patients randomly assigned (2:1) to four cycles BV-AVD or standard bleomycin, vincristine, (ABVD),...
Teclistamab shows promising results in R/R AL amyloidosis, with VGPR or better 88% of patients and involved FLC < 10 mg/L 76%. We observed a 35% rate severe infections no cardiac kidney related events.
6507 Background: Hypomethylating agent (HMA) plus venetoclax (VEN) regimens are standard of care in older/chemotherapy ineligible patients with acute myeloid leukemia (AML). While the VEN label recommends continuous 28-day cycles, shortened durations may mitigate cytopenias and improve tolerability. It is unknown how shorter cycles compare to HMA+VEN terms efficacy/safety. Methods: We performed a retrospective comparison newly diagnosed (ND) AML treated azacitidine (AZA) x 7 days (“7+7”...
We investigated using a custom NGS panel of 149 genes the mutational landscape 64 consecutive adult patients with tyrosine kinase fusion-negative hypereosinophilia (HE)/hypereosinophilic syndrome (HES) harboring features suggestive myeloid neoplasm. At least one mutation was reported in 50/64 (78%) (compared to 8/44 (18%) idiopathic HE/HES/HE
Red blood cell transfusions (RBCT) remain the cornerstone of supportive care in lower-risk myelodysplastic syndrome (LRMDS) [1]. Transfusion dependency LRMDS patients is associated with inferior outcomes, mainly attributed to severe bone marrow failure [2]. However, iron toxicity, due frequent RBCT or ineffective erythropoiesis, may be an additional negative prognostic factor [3,4,5,6]. Recently, much progress has been made unraveling metabolism. The peptide hormone hepcidin key regulator by...
Abstract Background: The Prognostic Inflammatory and Nutritional Index (PINI) is a simple scoring system that aggregates two blood markers of inflammatory [C‐reactive protein (CRP) orosomucoid] nutritional (albumin prealbumin) states. It used in routine practice geriatric medicine, especially hospitalized elderly patients. This study was undertaken to evaluate the usefulness PINI index multiple myeloma (MM), malignancy elderly. Method: score determined 231 previously untreated patients with...
Abstract CNS relapse is reported in 2–5% of diffuse large B‐cell lymphoma ( DLBCL ) patients, dramatically decreasing overall survival OS ). Very few studies address incidence and risk factors very elderly a challenging population to treat given their commonly associated comorbidities. A retrospective analysis was performed 270 patients >80 years treated between 2004 2013 two multicentre phase II LYSA trials LNH 03‐7B, 09‐7B) evaluating the addition rituximab or ofatumumab mini‐ CHOP as...